Kidney involvement, high anti-dsDNA predict lupus flares

Kidney involvement, high anti-dsDNA predict lupus flares
Kidney involvement and high anti-double stranded DNA are independent predictors of moderate-severe lupus flare, according to research published online June 10 in Arthritis & Rheumatism.

(HealthDay)—Kidney involvement and high anti-double stranded (ds) DNA are independent predictors of moderate-severe lupus flare, according to research published online June 10 in Arthritis & Rheumatism.

Michelle A. Petri, M.D., from Johns Hopkins University in Baltimore, and colleagues conducted post-hoc analysis to assess baseline demographics, , and biomarkers in 562 patients, treated with standard therapy alone, with and without flare at treatment weeks 24/52. Severe and moderate flares were defined using the modified SLE Flare Index (SFI) and the new British Isles Lupus Assessment Group (BILAG) A/B scores.

The researchers found that over 52 weeks the frequencies of SFI, BILAG 1A, and BILAG 1A/2B flares were 24, 23, and 32 percent, respectively. Using all three indices, in univariate analyses, predictors of flares at weeks 24/52 included: Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) ?12, anti-dsDNA positivity and proteinuria (?0.5 g/24 hours); BILAG renal, vasculitic, and hematologic scores; increased C-reactive protein; and B-lymphocyte stimulator (BLyS) ?2 ng/mL. In multivariate analysis, independent predictors at week 52 included: SELENA-SLEDAI/BILAG renal involvement and anti-dsDNA ?200 IU/mL (all three indices); SELENA-SLEDAI/BILAG neurologic and vasculitic involvement (BILAG A/2 B or 1A scores); BLyS ?2 ng/mL (SFI and BILAG 1A/2B scores); and low complement 3 (SFI).

"In summary, anti-dsDNA ?200 IU/mL and renal organ involvement at baseline were independent predictors of moderate-severe SLE flare at week 52 on all three flare indices," the authors write. "Close monitoring of patients with disease activity or biomarkers predictive of SLE flare may improve their care and long-term outcomes."

Several authors disclosed financial ties to GlaxoSmithKline and Human Genome Sciences, which supported the study.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Restrictions lifted at British bird flu farm

11 hours ago

Britain on Sunday lifted all restrictions at a duck farm in northern England after last month's outbreak of H5N8 bird flu, the same strain seen in recent cases across Europe.

Recorded Ebola deaths top 7,000

Dec 20, 2014

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

Dec 20, 2014

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.